se gb

Dilaforette to present at SCD Therapeutics Conference in New York

STOCKHOLM – 7th SEPTEMBER, 2016. Dilaforette, a Karolinska Development (STO:KDEV) portfolio company focused on developing sevuparin, an innovative treatment for patients with sickle cell disease, announces CEO Christina Herder is to present at the 5th Annual Sickle-Cell Disease (SCD) Therapeutics Conference on 8th September 2016 in New York.

In her presentation, Dr Herder will outline Dilaforette’s development plans for sevuparin, a novel drug that it believes could offer a significant improvement of treatments in SCD. Sevuparin has the potential to normalize the lives of SCD patients, either by:

  • Shortening hospital stays which result from an acute vaso-occlusive crisis (VOC); or
  • Abolishing the need for hospitalization via patients being able to self-administer the drug when they believe a VOC is imminent

Dilaforette is currently enrolling SCD patients into a multi-centre, international, randomized Phase II study in Europe and the Middle East (NCT02515838).

Dr Herder’s presentation will take place at the Four Seasons Hotel in New York, USA. The presentation will begin at 14:40.

The Annual Sickle-Cell Disease Therapeutics Conference is a forum to discuss the latest advancements and future trends for treating patients with sickle-cell disease. The event will feature presentations from clinical-stage companies, key opinion leaders, patients and healthcare analysts.

 

For further information, please contact:
Christina Herder, CEO:

Tel: +46 70 374 71 56

E-mail: christina.herder@dilaforette.se

David Dible/ Pip Batty, Citigate Dewe Rogerson

Tel: +44 20 7638 9571

E-mail: david.dible@citigatedr.co.uk

 

TO THE EDITORS

About Dilaforette

Dilaforette is a Swedish biotech company developing sevuparin - a new drug to treat people suffering from Sickle Cell Disease (SCD) – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow by reducing their pain and the amount of time they will need to spend in hospital. Dilaforette plans to develop a formulation of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.

Dilaforette is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.dilaforette.se

 

About Sevuparin

Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions, caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life. Dilaforette is currently enrolling patients in a Phase II study with the aim to present data during first half of 2017. Sevuparin has been granted Orphan Drug designations in both EU and US for treatment of SCD.

 

News release as PDF

2016-09-07